{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:04Z","timestamp":1791357364188,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009831","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,1,16]],"date-time":"2015-01-16T00:00:00Z","timestamp":1421366400000}}],"reference-count":232,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009831.pub2","type":"journal-article","created":{"date-parts":[[2015,1,16]],"date-time":"2015-01-16T09:37:43Z","timestamp":1421401063000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders"],"prefix":"10.1002","volume":"2015","author":[{"given":"Markus","family":"Dold","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"},{"name":"Medical University of Vienna; Department of Psychiatry and Psychotherapy; Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto T","family":"Samara","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbo","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Psychotic Disorders; 600 Wan Ping Nan Road Shanghai China 200030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdolna","family":"Tardy","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,16]]},"reference":[{"key":"10.1002\/14651858.CD009831.pub2-BIB0001|cit1","first-page":"105","article-title":"Psychopharmacological correlates of post psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia","volume":"43","author":"Abuzzahab","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0447.1993.tb03329.x","article-title":"A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis","volume":"87","author":"Baastrup","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/08039489009096565","article-title":"Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients - a controlled multicenter study","volume":"44","author":"Fensbo","year":"1990","journal-title":"Nordisk Psykiatrisk Tidsskrift"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0004|cit4","first-page":"305","article-title":"A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients","volume":"16","author":"Bechelli","year":"1983","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2007-1019585","article-title":"A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients","volume":"14","author":"Brannen","year":"1981","journal-title":"Pharmacopsychiatria"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0006|cit6","first-page":"47","article-title":"A double-blind comparative clinical trial with loxapine succinate and haloperidol in the treatment of Schizophrenia","volume":"78","author":"Bueno","year":"1979","journal-title":"Folha Medica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0009|cit7","first-page":"22","article-title":"The computer diagnosis in a multicenter study of psychoactive agents","volume":"12","author":"Cassano","year":"1976","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0007|cit8","first-page":"41","article-title":"Sulpiride - an antipsychotic agent: comparative trial vs. haloperidol","volume":"13","author":"Cassano","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0008|cit9","first-page":"189","article-title":"Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial","volume":"17","author":"Cassano","year":"1975","journal-title":"Current Therapy Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000468215","article-title":"An automated diagnostic process (PDA) in clinical psychopharmacology. An exemplification of its use in a sulpiride versus haloperidol comparative trial","volume":"11","author":"Castrogiovanni","year":"1976","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0011|cit11","first-page":"1109","article-title":"Droperidol: a double-blind clinical study","volume":"95","author":"Cocchi","year":"1971","journal-title":"Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0012|cit12","first-page":"1119","article-title":"Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol","volume":"20","author":"Cocito","year":"1970","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0924-977X(99)80341-1","article-title":"Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy","volume":"9","author":"Cosar","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0014|cit14","first-page":"171","article-title":"A double-blind comparison between pipotiazine and haloperidol","volume":"13","author":"Darondel","year":"1981","journal-title":"Psychologie Medicale"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000468454","article-title":"Clinical evaluation of bromperidol versus haloperidol in psychotic patients","volume":"15","author":"Denijs","year":"1980","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0016|cit16","first-page":"249","article-title":"Thioridazine improves affective symptoms in schizophrenic patients","volume":"29","author":"Dufresne","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0017|cit17","first-page":"834","article-title":"Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment","volume":"39","author":"Engelhardt","year":"1978","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0018|cit18","first-page":"15","article-title":"Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics","volume":"46","author":"Escobar","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1176\/ajp.126.11.1670","article-title":"Comparison of haloperidol and fluphenazine in disturbed children","volume":"126","author":"Faretra","year":"1970","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0020|cit20","first-page":"22","article-title":"Prediction of the therapeutic response to neuroleptics in schizophrenia","volume":"10","author":"Fuentenebro","year":"1989","journal-title":"Psiquis Revista de Psiquiatria, Psicologia y Psicosomatica"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD009831.pub2-BIB0021|cit21","first-page":"53","article-title":"Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action","volume":"3","author":"Gallant","year":"1967","journal-title":"International Journal of Neuropsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1176\/ajp.121.6.592","article-title":"Trifluperidol and haloperidol in the treatment of acute schizophrenia","volume":"121","author":"Pratt","year":"1964","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0023|cit23","first-page":"1309","article-title":"Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross-over study of therapeutic effectiveness,side effects and plasma concentrations. [article in french]","volume":"61","author":"Gerlach","year":"1985","journal-title":"Semaine des Hopitaux"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1192\/bjp.147.3.283","article-title":"Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations","volume":"147","author":"Gerlach","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08039488409101733","article-title":"Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]","volume":"38","author":"Munk-Andersen","year":"1984","journal-title":"Nordisk Psykiatrisk Tidsskrift"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0447.1984.tb06857.x","article-title":"Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report","volume":"311","author":"Munk-Andersen","year":"1984","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0027|cit27","first-page":"233","article-title":"Clinical therapeutic experience with bromperidol - a double-blind study","volume":"4","author":"Germana","year":"1990","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0028|cit28","first-page":"1803","article-title":"Comparative study of pipotiazine (in its non-esterified form) and of haloperidol in acute or subacute psychotic states","volume":"16","author":"Giordana","year":"1984","journal-title":"Psychologie Medicale"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0920-9964(90)90016-Z","article-title":"A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia","volume":"3","author":"Glazer","year":"1990","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0030|cit30","first-page":"4","article-title":"Molindone and haloperidol in tardive dyskinesia","volume":"46","author":"Glazer","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0031|cit31","first-page":"236","article-title":"Haloperidol in controlling the symptoms of acute psychoses. Part II. A double-blind evaluation of haloperidol and trifluoperazine","volume":"8","author":"Goldstein","year":"1966","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0033-3182(69)71755-8","article-title":"The differential prediction of response to two anti-psychotic drugs","volume":"10","author":"Goldstein","year":"1969","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0033|cit33","first-page":"487","article-title":"Pimozide (R6238) in chronic schizophrenia: double-blind trial","volume":"78","author":"Gowardman","year":"1973","journal-title":"New Zealand Medical Journal"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0034|cit34","first-page":"888","article-title":"Pimozide and haloperidol in a double-blind study in acutely schizophrenic patients","volume":"32","author":"Haas","year":"1982","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-2007-1019512","article-title":"Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study","volume":"15","author":"Haas","year":"1982","journal-title":"Pharmacopsychiatria"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0036|cit36","first-page":"405","article-title":"A controlled comparison of haloperidol and fluphenazine in chronic treatment-resistant schizophrenics","volume":"29","author":"Hall","year":"1968","journal-title":"Diseases of the Nervous System"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD009831.pub2-BIB0037|cit37","first-page":"30","article-title":"Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation","volume":"294","author":"Heikkil\u00e4","year":"1981","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1185\/03007999209111526","article-title":"Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study","volume":"12","author":"Heikkil\u00e4","year":"1992","journal-title":"Current Medical Research Opinion"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00005053-196212000-00007","article-title":"Controlled comparison of Haloperidol with thiopropazate in newly admitted schizophrenics","volume":"135","author":"Hollister","year":"1962","journal-title":"Journal of Nervous and Mental Disorders"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0040|cit40","first-page":"458","article-title":"Haloperidol for chronically hospitalized psychotics: a double-blind comparison with thiothixene and placebo; a follow-up open evaluation","volume":"35","author":"Howard","year":"1974","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0041|cit41","first-page":"105","article-title":"Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double-blind comparison of bromperidol and haloperidol","volume":"13","author":"Ito","year":"1985","journal-title":"Rinsho Hyoka (Clinical Evaluation)"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0042|cit42","first-page":"120","article-title":"A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double- blind technique","volume":"21","author":"Itoh","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/030006058301100202","article-title":"A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique","volume":"11","author":"Kariya","year":"1983","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0044|cit44","first-page":"1281","article-title":"Comparison of clinical effects of timiperone and haloperidol on schizophrenia using double-blind technique","volume":"10","author":"Kariya","year":"1981","journal-title":"Seishin Igaku (Clinical Psychiatry)"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0045|cit45","first-page":"365","article-title":"Possible predictors of neuroleptic-resistant schizophrenic relapse - influence of negative symptoms and acute extrapyramidal side effects","volume":"29","author":"Kinon","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0046|cit46","first-page":"309","article-title":"Treatment of neuroleptic-resistant schizophrenic relapse","volume":"29","author":"Kinon","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0047|cit47","first-page":"269","article-title":"The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double-blind method","volume":"12","author":"Kodama","year":"1984","journal-title":"Igaku to Yakugaku"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0048|cit48","first-page":"519","article-title":"Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine","volume":"12","author":"Kurihara","year":"1983","journal-title":"Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry)"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0049|cit49","first-page":"181","article-title":"A comparison of haloperidol and trifluoperazine. (A double-blind, controlled study on chronic schizophrenic outpatients)","volume":"28","author":"Luckey","year":"1967","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0050|cit50","first-page":"147","article-title":"Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients","volume":"78","author":"Malfroid","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0028-1094441","article-title":"The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research","volume":"1","author":"Mattke","year":"1975","journal-title":"Pharmakopsychiatrie und Neuropsychopharmakologie"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0052|cit52","first-page":"946","article-title":"A method for studying pupilomotorics under the influence of neuroleptic medication","volume":"26","author":"Mattke","year":"1976","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0053|cit53","first-page":"187","article-title":"Schizophrenic disorder in active phase: double-blind study between bromperidol and haloperidol","volume":"16","author":"Mauri","year":"1994","journal-title":"Giornale di Neuropsicofarmacologia"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0054|cit54","first-page":"349","article-title":"A double-blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia","volume":"17","author":"Mori","year":"1989","journal-title":"Rinsho Hyoka"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2007-1019599","article-title":"Initial improvement as predictor of outcome of neuroleptic treatment","volume":"14","author":"Nedopil","year":"1981","journal-title":"Pharmacopsychiatria"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00427763","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenics - a comparative dose-response study of haloperidol and propericiazine","volume":"82","author":"Nishikawa","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0057|cit57","first-page":"973","article-title":"Comparison of the clinical efficacy of methylperidol (luvatren) and haloperidol for schizophrenia by the double-blind method","volume":"4","author":"Nishimatu","year":"1975","journal-title":"Seishin Igaku (Clinical Psychiatry)"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0058|cit58","first-page":"75","article-title":"Management of hostile, suspicious patients - trifluoperazine versus haloperidol","volume":"35","author":"O'Brien","year":"1974","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0059|cit59","first-page":"439","article-title":"The efficacy of sulpiride in the treatment of schizophrenia by the double-blind method","volume":"7","author":"Okuda","year":"1979","journal-title":"Japanese Pharmacology and Therapeutics [Yakuri to Chiryo]"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0060|cit60","first-page":"32","article-title":"A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients","volume":"12","author":"Paprocki","year":"1976","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0061|cit61","first-page":"354","article-title":"Flupenthixol versus haloperidol in acute psychosis","volume":"3","author":"Parent","year":"1983","journal-title":"Pharmatherapeutica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0062|cit62","first-page":"617","article-title":"Flupenthixol versus haloperidol in acute psychotic episodes [article in french]","volume":"82","author":"Parent","year":"1982","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000468826","article-title":"Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double-blind research","volume":"13","author":"Bures","year":"1978","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0065|cit64","first-page":"96","article-title":"Clinical experiences in an open and a double-blind trial","volume":"78","author":"P\u00f6ldinger","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0064|cit65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000468306","article-title":"Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol","volume":"12","author":"P\u00f6ldinger","year":"1977","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0066|cit66","first-page":"99","article-title":"A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients","volume":"19","author":"Pool","year":"1976","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00431106","article-title":"A clinical and pharmacodynamic evaluation of sulpiride","volume":"73","author":"Rama Rao","year":"1981","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0068|cit68","first-page":"414","article-title":"A double-blind comparison of the onset of activity of haloperidol and trifluoperazine","volume":"8","author":"Rubin","year":"1971","journal-title":"Alabama Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0070|cit69","first-page":"645","article-title":"Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics","volume":"19","author":"Selman","year":"1976","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0069|cit70","first-page":"1533","article-title":"Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics [article in french]","volume":"11","author":"Selman","year":"1979","journal-title":"Psychologie M\u00e9dicale"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0075|cit71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000467995","article-title":"Consistency and similarity of drug EEG responses in chronic schizophrenic patients","volume":"8","author":"Serafetinides","year":"1973","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0076|cit72","first-page":"190","article-title":"Voltage laterality in the EEG of psychiatric patients","volume":"34","author":"Serafetinides","year":"1973","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0071|cit73","first-page":"263","article-title":"Psychological effects of single dose antipsychotic medication","volume":"7","author":"Serafetinides","year":"1973","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0072|cit74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00005053-197201000-00005","article-title":"Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives","volume":"154","author":"Serafetinides","year":"1972","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0074|cit75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000468000","article-title":"A method of quantifying EEG for psychopharmacological research","volume":"8","author":"Serafetinides","year":"1973","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0073|cit76","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00005053-197211000-00010","article-title":"Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics","volume":"155","author":"Serafetinides","year":"1972","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0447.1993.tb03335.x","article-title":"Poor neuroleptic response in acutely exacerbated schizophrenic patients","volume":"87","author":"Shalev","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0022-3956(84)90016-5","article-title":"The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol","volume":"18","author":"Silverstone","year":"1984","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0079|cit79","first-page":"67","article-title":"A double-blind comparative study of bromperidol versus haloperidol in schizophrenic patients","volume":"7","author":"Spina","year":"1992","journal-title":"New Trends in Experimental and Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0080|cit80","first-page":"23","article-title":"Haloperidol - new addition to the drug treatment of schizophrenia","volume":"1","author":"Stewart","year":"1969","journal-title":"Behavioral Neuropsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00048677509159857","article-title":"Tranquilizers or anti-depressants for chronic schizophrenics: a long term study","volume":"9","author":"Teja","year":"1975","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0082|cit82","first-page":"168","article-title":"Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia","volume":"5","author":"Tobin","year":"1980","journal-title":"Psychiatric Journal of the University of Ottowa"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0083|cit83","first-page":"126","article-title":"A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients","volume":"47","author":"Tuason","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0084|cit84","unstructured":"Ulmar G Edler R Hagen M Trifluperidol vs haloperidol \u2013 a double-blind trial Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan 1990 296"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0085|cit85","first-page":"559","article-title":"Double-blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients","volume":"24","author":"Versiani","year":"1978","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0165-1781(79)90014-3","article-title":"Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks","volume":"1","author":"Eaton","year":"1979","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000468472","article-title":"Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine","volume":"16","author":"White","year":"1981","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0088|cit88","first-page":"44","article-title":"Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses, affective psychoses and paranoid states: a controlled clinical trial","volume":"7","author":"Al Haddad","year":"1996","journal-title":"Arab Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0089|cit89","first-page":"321","article-title":"Clinical and acoustic measures of the negative syndrome","volume":"31","author":"Alpert","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1176\/ajp.117.6.546","article-title":"The effect of R-1625 (haloperidol) in mental syndromes: a multiblind study","volume":"117","author":"Azima","year":"1960","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2004.12.019","article-title":"Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers","volume":"77","author":"Barch","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0092|cit92","first-page":"199","article-title":"Pimozide treatment of chronic schizophrenics as compared with haloperidol and penfluridol maintenance treatment. A multidisciplinary approach","volume":"72","author":"Baro","year":"1972","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0093|cit93","first-page":"121","article-title":"Short term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia","volume":"12","author":"Bechelli","year":"1986","journal-title":"L'Encephale"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1017\/S0767399X0000095X","article-title":"Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools","volume":"2","author":"Boyer","year":"1987","journal-title":"Psychiatrie and Psychobiologie"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"Brook S Berk M Selemani S Kolloori J Nzo I A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1997","DOI":"10.1002\/(SICI)1099-1077(199801)13:1<17::AID-HUP937>3.0.CO;2-G"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1099-1077(199801)13:1<17::AID-HUP937>3.0.CO;2-G","article-title":"A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis","volume":"13","author":"Brook","year":"1998","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0097|cit97","first-page":"365","article-title":"A double-blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics","volume":"53","author":"Chin","year":"1998","journal-title":"Medical Journal of Malaysia"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2007-1016982","article-title":"Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine","volume":"21","author":"Classen","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0099|cit99","first-page":"86","article-title":"Haloperidol in geriatrics","volume":"6","author":"Cole","year":"1970","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0269881107066333","article-title":"A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia","volume":"21","author":"Costa","year":"2007","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.148.2.120","article-title":"A randomised controlled trial of prophylactic neuroleptic treatment","volume":"148","author":"Crow","year":"1986","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0102|cit102","first-page":"128","article-title":"British Journal of Psychiatry","volume":"148","author":"MacMillan","year":"1986","journal-title":"Short-term outcome in trial entrants and trial eligible patients"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/bjp.bp.106.028654","article-title":"Cost-effectiveness of first- v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy","volume":"191","author":"Davies","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00406-004-0514-1","article-title":"The prevalence of tardive dyskinesia after a nine month naturalistic randomised trial comparing olanzapine with conventional treatment for schizophrenia and related disorders","volume":"254","author":"Jesus Mari","year":"2004","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0105|cit105","first-page":"75","article-title":"Use of a new butyrophenone in psychiatric service. Outline of a differential study","volume":"56","author":"Digo","year":"1967","journal-title":"L'Encephale"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0106|cit106","first-page":"475","article-title":"Rapid tranquilization: the efficacy of oral concentrate","volume":"46","author":"Dubin","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0107|cit107","first-page":"70","article-title":"An early evaluation of haloperidol","volume-title":"The Butyrophenones in Psychiatry","author":"Durost","year":"1964"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004714-198706000-00011","article-title":"Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol","volume":"7","author":"Ehmann","year":"1987","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1600-0447.1992.tb01446.x","article-title":"Effects of antipsychotic drugs on memory functions of schizophrenic patients","volume":"85","author":"Eitan","year":"1992","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF01537988","article-title":"A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children","volume":"3","author":"Engelhardt","year":"1973","journal-title":"Journal of Autism and Childhood Schizophrenia"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0111|cit111","first-page":"515","article-title":"A double-blind comparison of haloperidol with perphenazine","volume":"11","author":"Fitzgerald","year":"1969","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0006-3223(94)90002-7","article-title":"QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients","volume":"35","author":"Galderisi","year":"1994","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00427742","article-title":"Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine","volume":"59","author":"Gerlach","year":"1978","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0114|cit114","first-page":"224","article-title":"The effects of selected antipsychotic drugs of human judgment","volume":"21","author":"Gillis","year":"1977","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0115|cit115","first-page":"87","article-title":"High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics","volume":"28","author":"Harris","year":"1992","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0116|cit116","first-page":"173","article-title":"Assessment and significance of changes in laboratory values with haloperidol and fluphenazine hydrochloride therapy","volume":"2","author":"Holden","year":"1970","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2005.05.001","article-title":"Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan","volume":"80","author":"Huang","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0118|cit118","first-page":"1296","article-title":"The clinical psychopharmacological efficacy of bromperidol for schizophrenia comparison with haloperidol by the single-blind cross-over method","volume":"21","author":"Hyugano","year":"1986","journal-title":"Shinryo to Shinyaku"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00005053-197503000-00005","article-title":"Computerized EEG: predictor of outcome in schizophrenia","volume":"160","author":"Itil","year":"1975","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0121|cit121","first-page":"39","article-title":"Neuroleptic treatment of oligophrenic patients. A double-blind clinical multicentre trial of cis(z)-clopenthixol and haloperidol","volume":"294","author":"Karsten","year":"1981","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archpsyc.1972.01750250086012","article-title":"Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0278-5846(84)90138-6","article-title":"Rapid tranquilization - a comparative study of thiothixene and haloperidol","volume":"8","author":"Kelwala","year":"1984","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0124|cit124","first-page":"155","article-title":"Comparison of cardiac influences of antipsychotic drugs in patients with schizophrenia","volume":"17","author":"Kurt","year":"2007","journal-title":"Klinik Psikofarmakoloji B\u00fclteni"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/13651500310000906","article-title":"Zuclopenthixol versus haloperidol: an observational randomised pharmacoeconomic evaluation of patients with chronic schizophrenia exhibiting acute psychosis","volume":"7","author":"Lamure","year":"2003","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0126|cit126","first-page":"36","article-title":"The effectiveness of combined phenothiazine and butyrophenone treatment in chronic schizophrenic patients","volume":"9","author":"Lehmann","year":"1967","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0127|cit127","first-page":"695","article-title":"Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol","volume":"20","author":"Levenson","year":"1976","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0128|cit128","first-page":"685","article-title":"Difference in prolactin response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride","volume":"12","author":"Liu","year":"1996","journal-title":"Kao Hsiung I Hsueh Ko Hsueh Tsa Chih Kaohsiung (Journal of Medical Sciences)"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0129|cit129","first-page":"234","article-title":"Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol","volume":"48","author":"Lovett","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0924-977X(91)90008-I","article-title":"Zuclopenthixol, a combined dopamine D1\/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia","volume":"1","author":"Lublin","year":"1991","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1192\/bjp.166.3.374","article-title":"Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients","volume":"166","author":"Malt","year":"1995","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0132|cit132","first-page":"47","article-title":"Effect and tolerability of clopixol and haloperidol in patients with acute symptoms of schizophrenia: comparative randomised investigation","volume":"10","author":"Mosolov","year":"2000","journal-title":"Sotsial'naia I Klinicheskaia Psikhiatria"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0133|cit133","first-page":"219","article-title":"Blind comparison of oxyprothepin and haloperidol in six-week treatment periods in schizophrenia","volume":"24","author":"Nahunek","year":"1982","journal-title":"Activitas Nervosa Superior"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0134|cit134","first-page":"227","article-title":"Tardive dyskinesia: pathophysiological mechanisms and clinical trials","volume":"14","author":"Gerlach","year":"1988","journal-title":"L'Encephale"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0135|cit135","first-page":"423","article-title":"Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden","volume":"90","author":"Nordic Dyskinesia Study Group","year":"1986","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0136|cit136","first-page":"1682","article-title":"The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden","volume":"25","author":"Povlsen","year":"1987","journal-title":"Ugeskrift for Laeger"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0137|cit137","first-page":"3349","article-title":"The double-blind comparative study of bromperidol and haloperidol in the treatment of schizophrenic inpatients","volume":"18","author":"Onodera","year":"1984","journal-title":"Kiso to Rinsho"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0138|cit138","first-page":"80","article-title":"A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia","volume":"21","author":"Paprocki","year":"1977","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0139|cit139","first-page":"167","article-title":"Neuroleptics election and clinical outcomes in acute psychosis: a comparative study of risperidone versus other neuroleptics","volume":"20","author":"Pedros Rosello","year":"2004","journal-title":"Anales de Psiquiatria"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-006-0611-0","article-title":"Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol","volume":"190","author":"Reimold","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00004714-200008000-00004","article-title":"Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics","volume":"20","author":"Reznik","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0142|cit142","first-page":"434","article-title":"Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy","volume":"1986","author":"Saletu","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1176\/ajp.118.3.253","article-title":"A controlled study of haloperidol: the effects of small dosages","volume":"11","author":"Samuels","year":"1961","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1176\/ajp.141.11.1455","article-title":"Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol","volume":"141","author":"Serban","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0145|cit145","first-page":"407","article-title":"A controlled study of haloperidol in chronic schizophrenia","volume":"9","author":"Simpson","year":"1967","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0146|cit146","first-page":"413","article-title":"Further studies on the effect of butyrophenones on cholesterol synthesis in humans","volume":"9","author":"Simpson","year":"1967","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0147|cit147","first-page":"191","article-title":"Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance","volume":"37","author":"Singh","year":"1976","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0148|cit148","first-page":"173","article-title":"Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance","volume":"2","author":"Singh","year":"1974","journal-title":"Journal of the Bronx State Hospital"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0165-1781(85)90019-8","article-title":"Lateral ventricular enlargement and clinical response in schizophrenia","volume":"14","author":"Smith","year":"1985","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0150|cit150","first-page":"967","article-title":"Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients","volume":"38","author":"Stotsky","year":"1977","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0151|cit151","doi-asserted-by":"crossref","unstructured":"Su KP Chen KP Shen WW Tsai SY QTc prolongation associated with sulpiride and haloperidol use: a pilot crossover-design study European Neuropsychopharmacology 2000 311 2","DOI":"10.1016\/S0924-977X(00)80362-4"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(01)00336-X","article-title":"A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol","volume":"59","author":"Su","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0153|cit153","first-page":"1301","article-title":"Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients","volume":"85","author":"Taymeeyapradit","year":"2002","journal-title":"Journal of the Medical Association of Thailand"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0154|cit154","first-page":"24","article-title":"Comparison of influence of perazine, fluphenazine, trifluoroperazine, chloropromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia","volume":"1","author":"Terminska","year":"1989","journal-title":"Psychiatria Polska"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0155|cit155","first-page":"1072","article-title":"The influence of haloperidol and penfluridol on the learning capacity of the schizophrenic","volume":"24","author":"Lommel","year":"1974","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archpsyc.1983.01790220026004","article-title":"Akathisia with haloperidol and thiothixene","volume":"41","author":"Putten","year":"1984","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0157|cit157","first-page":"12","article-title":"Low-dose treatment strategies","volume":"47","author":"Putten","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0158|cit158","first-page":"35","article-title":"Comparative clinical study of nemonapride, a benzamide compound with dopamine D-2-like receptor blocking activity, and haloperidol in schizophrenic patients","volume":"24","author":"Zuoning","year":"1999","journal-title":"Research Communications in Biological Psychology and Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD009831.pub2-BIB0159|cit159","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003082.pub3","article-title":"Haloperidol versus placebo for schizophrenia","author":"Adams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009831.pub2-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD009831.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0162|cit162","volume-title":"Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde","author":"AMDP","year":"2007"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0163|cit163","volume-title":"The Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1983"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/S0007125000291496","article-title":"Scale for the assessment of negative symptoms","volume":"155","author":"Andreasen","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0165|cit165","volume-title":"Psychische Erkrankungen. Klinik und Therapie. 2nd edition","author":"Berger","year":"2003"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0167|cit167","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009831.pub2-BIB0169|cit169","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001943.pub2","article-title":"Loxapine for schizophrenia","author":"Chakrabarti","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0170|cit170","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4613-4042-3_4","article-title":"Neuroleptics: clinical use in psychiatry","volume-title":"Handbook of Psychopharmacology","author":"Davis","year":"1978"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0171|cit171","article-title":"Antipsychotic drugs","volume-title":"Comprehensive Textbook of Psychiatry","author":"Davis","year":"1989"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0172|cit172","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der-Simonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD009831.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009831.pub2-BIB0175|cit175","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(97)02419-7","article-title":"Language bias in randomised controlled trials published in English and German","volume":"350","author":"Egger","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD009831.pub2-BIB0179|cit179","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059.pub2","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Essali","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia","volume":"6","author":"Falkai","year":"2005","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research","volume":"26","author":"Feighner","year":"1972","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0183|cit183","volume-title":"Behandlungsleitlinie Schizophrenie","author":"Gaebel","year":"2006"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1176\/ajp.110.5.334","article-title":"Rating Scale for Quantification of Psychotic Symptom Severity (RSQPSS)","volume":"110","author":"Goodrich","year":"1953","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0186|cit186","volume-title":"ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale)","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009831.pub2-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003443.pub2","article-title":"Perphenazine for schizophrenia","author":"Hartung","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0189|cit189","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD009831.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1097-4679(196501)21:1<65::AID-JCLP2270210122>3.0.CO;2-I","article-title":"Nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia","volume":"21","author":"Honigfeld","year":"1965","journal-title":"Journal of Clinical Psychology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/15622975.2010.551544","article-title":"Meta-analysis: fact or fiction? How to interpret meta-analyses","volume":"12","author":"Huf","year":"2011","journal-title":"World Journal of Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009831.pub2-BIB0192|cit192","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000440","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","author":"Hunter","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009831.pub2-BIB0193|cit193","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000525.pub3","article-title":"Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses","author":"Jayakody","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0194|cit194","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2125.2003.01905.x","article-title":"Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study","volume":"56","author":"Kaye","year":"2003","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0197|cit197","article-title":"Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins, 1969","volume-title":"Diagnosis and Drug Treatment of Psychiatric Disorders","author":"Klein","year":"1969"},{"issue":"1","key":"10.1002\/14651858.CD009831.pub2-BIB0198|cit198","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010226","article-title":"Trifluoperazine versus placebo for schizophrenia","author":"Koch","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","article-title":"Pharmacokinetics of haloperidol: an update","volume":"37","author":"Kudo","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0200|cit200","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD009831.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD009831.pub2-BIB0206|cit206","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004278.pub2","article-title":"Haloperidol versus chlorpromazine for schizophrenia","author":"Leucht","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0209|cit209","first-page":"767","article-title":"Psychopharmaka","volume-title":"Arzneimittelverordnungsreport","author":"Lohse","year":"2009"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment ? a review","volume":"39","author":"Marvaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0212|cit212","first-page":"1061","article-title":"Development of a schizophrenia scale sensitive to change","volume":"17","author":"Montgomery","year":"1978","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD009831.pub2-BIB0213|cit213","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001949.pub3","article-title":"Pimozide for schizophrenia or related psychoses","author":"Mothi","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0269881103017002012","article-title":"Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients","volume":"17","author":"Paton","year":"2003","journal-title":"Journal of Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD009831.pub2-BIB0216|cit216","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010832","article-title":"Fluphenazine (oral) versus atypical antipsychotics for schizophrenia","author":"Sampford","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"The Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1745-6215-11-32","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"11","author":"Schulz","year":"2010","journal-title":"Trials"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading Quality of Evidence and Strength of Recommendations for Diagnostic Tests and Strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"issue":"11","key":"10.1002\/14651858.CD009831.pub2-BIB0221|cit221","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009777.pub2","article-title":"Flupenthixol versus placebo for schizophrenia","author":"Shen","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009831.pub2-BIB0222|cit222","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001357","article-title":"Amisulpride for schizophrenia","author":"Silveira da Mota Neto","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009831.pub2-BIB0223|cit223","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000967.pub2","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD009831.pub2-BIB0224|cit224","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009268","article-title":"Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD009831.pub2-BIB0225|cit225","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009369","article-title":"Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD009831.pub2-BIB0226|cit226","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009230","article-title":"Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD009831.pub2-BIB0227|cit227","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009396","article-title":"Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD009831.pub2-BIB0228|cit228","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009227","article-title":"Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0230|cit230","first-page":"249","article-title":"Essential drugs","volume":"13","author":"World Health Organization (WHO)","year":"2009","journal-title":"WHO Drug Information"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1192\/bjp.107.450.862","article-title":"A simple and reliable subclassification of chronic schizophrenia","volume":"107","author":"Wing","year":"1961","journal-title":"Journal of Mental Science"},{"key":"10.1002\/14651858.CD009831.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009831.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T10:48:50Z","timestamp":1705229330000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009831.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,16]]},"references-count":232,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009831.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,16]]}}}